Keywords
Inhibidores de la acetilcolinesterasa
Tratamiento farmacológico
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To understand the role of acetylcholinesterase inhibitors in the treatment of Myasthenia Gravis. Methods: An integrative literature review was conducted in the PubMed, SciELO, and MedLine databases, considering articles published between 2014 and 2024. Studies in Portuguese and English addressing the use of acetylcholinesterase inhibitors (ACEIs) in the management of Myasthenia Gravis were included. After applying the inclusion and exclusion criteria, 24 articles were selected for full analysis. Results: The reviewed studies showed that ACEIs act by increasing the availability of acetylcholine at the neuromuscular junction, which significantly improves muscle strength and reduces patient fatigue. However, they do not interfere with the autoimmune process of the disease and may trigger undesirable cholinergic effects, such as diarrhea, abdominal cramps, and bronchoconstriction, limiting the ideal therapeutic dose. It was also observed that the clinical response varies among patients, requiring continuous monitoring and individual dose adjustment. Final considerations: ACE inhibitors are indispensable in the symptomatic management of Myasthenia Gravis, but their adverse effects reinforce the need for individualized follow-up.
References
AYRES A, et al. Did the speech of patients with myasthenia gravis decline over 4 years? Codas, 2024; 36(2): e20230055.
BARAKY TC, SIQUEIRA EC. Miastenia gravis. Revista Eletrônica Acervo Saúde, 2023; 23(7): e12726.
BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Miastenia Gravis. Brasília: Ministério da Saúde, 2021.
CRISAFULLI S, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs, 2024; 38(1): 15-32.
DRESSER L, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med, 2021; 10(11): 2235.
ESTEPHAN EP, et al. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr, 2022; 80(Supl 1): 257-265.
GALDEANO C, et al. Increasing polarity in tacrine and huprine derivatives: potent anticholinesterase agents for the treatment of myasthenia gravis. Molecules, 2018; 23(3): 634.
GAMBINO CM, et al. Detection of antibodies against the acetylcholine receptor in patients with myasthenia gravis: a comparison of two enzyme immunoassays and a fixed cell-based assay. J Clin Med, 2023; 12(14): 4781.
GILHUS NE, et al. Myasthenia gravis. Nat Rev Dis Primers, 2019; 5(1): 30.
IVOSEVIC A, et al. Mechanism and clinical importance of respiratory failure induced by anticholinesterases. Serb J Exp Clin Res, 2017; 18(4): 349-354.
LASCANO A, et al. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev, 2021; 20(1): 102712.
MARCONI MA, LAKATOS EM. Técnicas de pesquisa. 9.ed. São Paulo: Atlas, 2021.
MEHNDIRATTA MM, et al. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev, 2014; 10: CD006986.
ODIERNA GL, PHILLIPS W. Targeting the safety factor for neuromuscular transmission to treat myasthenia gravis. Res Rep Neuromuscul Dis, 2023; 4(3): 19543.
OJHA PT, et al. The clinical outcome in AChR-positive generalized myasthenia gravis: a retrospective observational study. Ann Indian Acad Neurol, 2023; 26(4): 395-400.
PETROV KA, et al. Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment. Sci Rep, 2018; 8(1): 304.
POHANKA M. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci, 2014; 15(6): 9809-9825.
RICCIARDI R, et al. Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients. J Neurol Sci, 2024; 461: 123047.
ROTKIEWICZ D, et aI. Nawożenie siarką a valor de uso e tecnológica das sementes de colza de inverno. Rosliny Oleiste, 1996; 17: 257-264.
SCHNEIDER-GOLD C, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord, 2019; 12: 175628641983224.
SURYADEVARA V, et al. Comparing safety and efficacy of rituximab and eculizumab in treating refractory myasthenia gravis: a systematic review. J Immunol Med Graduates, 2023; 2(2): 138.
TOMSCHIK M, et al. The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis. Sci Rep, 2023; 13(1): 2985.
VANOLI F, et al. What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis? Expert Opin Pharmacother, 2022; 23(13): 1471-1474.
VEMURI D, et al. Disease severity assessment and short-term outcome in patients with myasthenia gravis. Ann Indian Acad Neurol, 2020; 23(2): 215-219.
YOSHIKAWA H. Autoimmunity to acetylcholine receptor channels. Neurol Clin Neurosci, 2022; 12(3): 143-149.
ZIAADINI B, et al. A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: a single-center experience. Curr J Neurol, 2022; 21(2): 91-97.